Catherine Orrell

Catherine Orrell publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Catherine Orrell sits on this spectrum.

Catherine Orrell D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Catherine Orrell sits on this spectrum.

Best Publications

• Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.

  Melanie A. Thompson;Michael J. Mugavero;K. Rivet Amico;Victoria A. Cargill

  533
  Citations

• Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design.

  Stephen D Lawn;Landon Myer;Catherine Orrell;Linda-Gail Bekker

  479
  Citations

• Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

  Lawrence Corey;Peter B Gilbert;Michal Juraska;David C Montefiori

  478
  Citations

• Adherence is not a barrier to successful antiretroviral therapy in South Africa.

  Catherine Orrell;David R. Bangsberg;Motasim Badri;Robin Wood

  465
  Citations

• Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial

  Ian Sanne;Catherine Orrell;Matthew P Fox;Francesca Conradie

  340
  Citations

• Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

  Edgar T Overton;Gary Richmond;Giuliano Rizzardini;Hans Jaeger

  327
  Citations

• Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation.

  Stephen D. Lawn;Landon Myer;Guy Harling;Catherine Orrell

  309
  Citations

• Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality.

  Martin W. G. Brinkhof;Andrew Boulle;Ralf Weigel;Eugène Messou

  268
  Citations

• Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa.

  Linda-Gail Bekker;Landon Myer;Catherine Orrell;Steve Lawn

  222
  Citations

• Linkage to HIV Care and Antiretroviral Therapy in Cape Town, South Africa

  Katharina Kranzer;Katharina Kranzer;Jennifer Zeinecker;Philip Ginsberg;Catherine Orrell

  208
  Citations

• Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations

  Jessica E. Haberer;Lora Sabin;K. Rivet Amico;Catherine Orrell

  193
  Citations

• Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.

  Catherine Orrell;Guy Harling;Stephen D Lawn;Richard Kaplan

  176
  Citations

• Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.

  Andrew Boulle;Catherine Orrel;Richard Kaplan;Gilles Van Cutsem

  173
  Citations

• Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa

  Stephen D Lawn;Francesca Little;Linda-Gail Bekker;Richard Kaplan

  172
  Citations

• Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.

  Olivia Keiser;Catherine Orrell;Matthias Egger;Matthias Egger;Robin Wood

  170
  Citations

• Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors.

  Katharina Kranzer;James J Lewis;Nathan Ford;Jennifer Zeinecker

  166
  Citations

• Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

  Jean-Michel Molina;Kathleen Squires;Paul E Sax;Pedro Cahn

  165
  Citations

• Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme.

  Stephen D Lawn;Linda-Gail Bekker;Landon Myer;Catherine Orrell

  161
  Citations

• Changes in Programmatic Outcomes During 7 Years of Scale-up at a Community-Based Antiretroviral Treatment Service in South Africa

  Nglazi;Lawn Sd;Kaplan R;Kranzer K

  158
  Citations

• Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.

  Olivia Keiser;Benjamin H. Chi;Thomas Gsponer;Andrew Boulle

  154
  Citations